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The Journal of Immunology
Early Emergence of CD19-Negative Human Antibody-
Secreting Cells at the Plasmablast to Plasma Cell Transition
Gururaj Arumugakani,* Sophie J. Stephenson,† Darren J. Newton,† Andy Rawstron,‡
Paul Emery,* Gina M. Doody,† Dennis McGonagle,* and Reuben M. Tooze†,‡
Long-lived human plasma cells (PCs) play central roles in immunity and autoimmunity and are enriched among the subpopulation
of CD19neg human PCs. However, whether human CD19neg PCs are necessarily aged cells that have gradually lost CD19 expres-
sion is not known. Assessing peripheral blood samples at steady-state and during the acute response to influenza vaccination in
healthy donors, we identify the presence of phenotypic CD19neg plasmablasts, the proliferative precursor state to mature PCs, and
demonstrate by ELISPOT that these are Ab-secreting cells (ASCs). During the acute response to influenza vaccination, CD19pos,
CD19low, and CD19neg ASCs secrete vaccine-specific Abs and show linked IGHV repertoires. To address precursor/product
relationships, we use in vitro models that mimic T-dependent and T-independent differentiation, finding that the CD19neg state
can be established at the plasmablast to PC transition, that CD19neg PCs increase as a percentage of surviving PCs in vitro, and
that CD19neg and CD19pos PCs can be maintained independently. These data provide proof-of-principle for the view that newly
generated ASCs can acquire a mature PC phenotype that is accompanied by loss of CD19 expression at an early stage of
differentiation and that aging is not an obligate requirement for a CD19neg state to be established. The Journal of Immunology,
2017, 198: 000–000.
L
ong-lived plasma cells (LLPCs) have emerged as major
contributors to humoral immunity (1, 2). The indepen-
dence of this population of Ab-secreting cells (ASCs)
from the B cell pool has profound implications for therapeutic
intervention in Ab-driven immune pathologies (3). Serological
analyses have suggested that the lifespan of human LLPCs may
approach that of the individual (2, 4); in a recent elegant study,
lifespans of decades have been inferred using carbon-14 dating
approaches (5). Extended plasma cell (PC) lifespans have been
demonstrated in mice (6, 7), and much interest has focused on
characterizing potential survival mechanisms for such LLPCs,
which may include elements intrinsic to the PC program (8–10) or
related to the PC niche (11–15).
One important approach, of particular relevance to studies of
human PC biology, is to identify surface phenotypes that may
define underlying functional heterogeneity and link to PC longevity
(16, 17). LLPCs are considered to reside principally in the bone
marrow (BM), although the recent data of Landsverk et al. (5)
have now also directly documented these in the small intestine.
One of the major markers of phenotypic heterogeneity among
human BM and intestinal PCs is the retention or loss of CD19
expression. Indeed, the absence of CD19 expression is charac-
teristic of neoplastic PCs in early and advanced PC malignancies
(18, 19), supporting the importance of distinguishing PC sub-
populations based on CD19 phenotypic state.
CD19 is a coreceptor of the BCR complex and is one of the
earliest and most specific markers of B-lineage commitment. In
humans, the majority of PCs retain expression of CD19, whereas a
minority of normal PCs lack CD19 expression (18, 20, 21). Recent
studies by Mei et al. (16) and subsequently by Halliley et al. (17)
indicated that BM (CD19neg) PCs are enriched for long-lived cells;
these have been followed by the demonstration of a similar phe-
notypic association for small intestinal PCs (5). The direct asso-
ciation of CD19neg PCs as a source of the long-lived anti-viral Ab
response was demonstrated in an index individual in the work of
Halliley et al. (17), and this association was further supported by
the enrichment of vaccine-specific Abs determined by ELISPOT
in the CD19neg PC fraction of multiple individuals. In patients
treated with anti-CD19 chimeric AgR T cell therapy, which se-
lectively eliminates B cells and CD19-expressing PCs, the main-
tenance of CD19neg PCs and associated vaccine/pathogen-specific
IgG and IgA responses has provided further evidence for the in-
dependent maintenance of this PC fraction and accompanying
long-lived immunity (22). Extending this phenotypic association
beyond the BM, CD19neg PCs in human small intestine were
linked to virus-specific immunity and were identified as two
phenotypic fractions of CD45pos or CD45neg CD19neg PCs (5). In
an elegant approach, a direct inference of average PC age was
made using carbon-14 dating, which indicated a median age of 11
and 20 y for CD45pos and CD45neg CD19neg PC populations, re-
spectively, in the small intestine. Intriguingly, this study also
identified a greater variability in the inferred average age for the
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CD45pos CD19neg PCs fraction, including an average age of 0 y
for such cells in two of six individuals tested (5).
PCs are derived from B cells by a process of transcriptional
reprogramming and specialization for committed Ab secretion
(23). This functional specialization is coupled to extinction of
many elements of the pre-existing B cell gene-expression pro-
gram. The consequent transitions in surface marker expression
contribute to the identification of distinct stages of B cell differ-
entiation, including the activated B cell/preplasmablast, plasma-
blast (PB), and PC states (24–26). The distinction between the PB
and PC states in humans is closely linked to acquisition of surface
CD138 expression, but it is strictly defined by entry into cell cycle
quiescence (27). Therefore, the encompassing term ASCs is used
to include the PB and PC states when the proliferative state is not
defined. How CD19pos and CD19neg PCs are generated in humans
is not known, and two distinct models can be envisaged. The first
is that CD19pos PCs gradually lose CD19 expression accompa-
nying prolonged ageing in an appropriate niche environment;
absence of CD19 would then provide a marker of PC age. The
second model is that loss or retention of CD19 may be established
during the initial phase of commitment to the PC state, with
subsequent recruitment into the long-lived pool. Indeed, these two
models are not necessarily mutually exclusive, but the second
model would imply that absence of CD19 expression does not
necessarily identify an individual PC or group of PCs as aged. In
this article, we address whether CD19neg ASCs emerge early
during PC differentiation in vivo in the response to influenza
vaccination, as well as in the context of in vitro model systems
that allow the sequential tracking of cell states in a differentiating
human ASC population, providing proof of principle for early
emergence of CD19neg ASCs in vitro and in vivo.
Materials and Methods
Samples and cell isolation
Approval for this study was provided by the U.K. National Research Ethics
Service via the Leeds East Research Ethics Committee (approval reference:
07/Q1206/47). The use of surplus clinical samples from anonymous patients and
controls was approved by the Leeds Teaching Hospitals Research Ethics Com-
mittee (approval reference: 04/Q1107/40).
Peripheral blood was obtained from healthy donors after informed
consent. Samples from healthy volunteers selected from within the aca-
demic environment, without evidence of recent infection or other clinical
condition, undergoing routine annual seasonal influenza vaccine were
collected at the specified time points. Sequential sampling for time-course
experiments derived from seasonal influenza vaccination in 2014, whereas
ELISPOT and IGHV sequence analysis derived from seasonal influenza
vaccination in 2015. All vaccines were delivered as part of routine vac-
cination programs for National Health Service and University staff, with
ELISPOT and IGHV sequences relating to vaccination with inactivated
influenza vaccine (Split Virion) BP 2015/2016 strain. Donors included
were between 25 and 50 y of age, and BM aspirates were from anonymous
donors and were derived from surplus clinical samples assessed as normal
by clinical flow cytometry. RBCs were lysed (ammonium chloride 8.6 g/l)
before flow cytometric analysis. Mononuclear cells were isolated by
Lymphoprep (Alere) density gradient centrifugation. Total B cells were
isolated by negative selection with a Memory B Cell Isolation Kit,
according to the manufacturer’s instructions (Miltenyi Biotec).
Abs and reagents
Abs used were CD19 PE (LT19; Miltenyi Biotec), CD138 allophycocyanin
(B-B4; Miltenyi Biotec), CD38 PE-Cy7 (HB7; BD Biosciences), CD38
AF700 (HIT2; BioLegend), CD20 eFluor V450 (2H7; eBioscience); CD27
AF647 (LT27; AbD Serotec), CD27 FITC (M-T271), CD19 PerCP-Cy5.5
(SJ225C1; BD Biosciences), CD19 PE-Cy7 (SJ225C1; BD Biosciences),
CD24 FITC (ML5; BD Biosciences), CD84 PE (CD84.1.21; BioLegend),
CD38 PerCP-Cy5.5 (HIT2; BD Biosciences), CD95 BV421 (DX2; Bio-
Legend), CD20 allophycocyanin-H7 (L27; BD Biosciences), CD27 BV605
(O323; BioLegend), CD3 VioGreen (BW264/56; Miltenyi Biotec), Ki67
FITC (B56; BD Biosciences), unconjugated goat anti-IRF4 (M-17; Santa
Cruz Biotechnology), and donkey anti-goat IgG AF488 (polyclonal;
Invitrogen). Controls were isotype-matched mouse mAbs. Annexin V
FITC was from eBioscience, and 7-AAD was from BD Biosciences.
Reagents included human IL-2 (Roche), IL-6 (PeproTech), IFN-a
(Sigma), IL-21 (PeproTech), goat anti-human F(ab9)2 fragments (anti-IgM
and anti-IgG; Jackson ImmunoResearch), HybridoMax hybridoma growth
supplement (Gentaur), Lipid Mixture 1, Chemically Defined (2003), and
MEM Amino Acids Solution (503, Sigma).
Flow cytometry and cell sorting
Cells were analyzed using direct immunofluorescence staining on a BD LSR
II Fortessa flow cytometer (BD Biosciences). Cell populations were gated
on forward scatter and side scatter profiles for viable cells, and costaining
with Annexin V FITC and 7-AAD was also used to exclude dead cells for
in vitro experiments. Analysis was performed with BD FACSDiva Software
8.0 (BD Biosciences). For in vitro experiments, cells were sorted based on
CD19 or CD27 expression with MoFlo high-speed cell sorter (Beckman
Coulter) or a BD Biosciences Influx, at the indicated time points. Graphic
overlays were generated with FlowJo Vx, and the rest of the flow cytometry
plots were generated with FACSDiva V8.0. Statistical analysis was per-
formed with GraphPad Prism 6.
Absolute cell counts were performed with CountBright beads (Invi-
trogen) for in vitro experiments. Dual-platform methodology, with cell
counts from Sysmex K-1000, was used for peripheral blood B cell counts.
Intracellular staining was performed with a BD IntraSure Kit (BD
Biosciences).
Peripheral blood was obtained from healthy donors at 6–8 d (influenza-
specific response) or 67+ d postvaccination (baseline). Mononuclear cells
were isolated by Lymphoprep (Alere) density gradient centrifugation.
T cells were depleted with CD3 magnetic beads (Miltenyi Biotec) prior to
cell sorting on a BD Influx (BD Biosciences). ASCs were then sorted on
their forward/side scatter profile and surface expression of CD27high
/CD38high/CD32/CD202. These cells were then further separated into
CD19pos, CD19low, and CD19neg populations, as depicted in Fig. 1.
ELISPOT
For detection of influenza-specific Ig, polyvinylidene difluoride plates were
activated with 70% ethanol, washed with sterile water, and coated with
human influenza vaccine (2.25 mg per well in sterile PBS) overnight at 4˚C.
Plates were then washed with sterile PBS and blocked with IMDM con-
taining 10% FBS, IL-21 (100 ng/ml), and IL-6 (20 ng/ml). Cells were
added at the indicated number in IMDM containing 10% FBS. Plates were
then incubated for 18–24 h in a humidified incubator. Following incuba-
tion, cells were removed, and plates were washed with PBS. To detect
influenza-specific IgG secretion, plates were incubated with IgG–MT78–
Biotin (1 mg/ml in PBS/0.5% BSA) for 2 h, washed with PBS, and in-
cubated with Streptavidin-HRP for an additional hour. Plates were washed,
and spots were detected by addition of TMB substrate solution. Images
were captured using an AID EliSpot Reader System with software version
5.0 (Autoimmun Diagnostika).
Detection of typhoid-specific Ig was carried out in a similar manner, with
the exception that plates were coated with Purified Vi Capsular Polysaccharide
of Salmonella enterica, serovar Typhi (1.5 mg per well in sterile PBS).
Vaccines used for coating plates were inactivated Influenza vaccine (Split
Virion) BP 2015/2016 strain and Typhim Vi Purified Vi Capsular Poly-
saccharide of Salmonella Typhi (Ty 2 Strain), both manufactured by Sanofi
Pasteur MSD.
For detection of human IgG secretion, a Human ELISpotPLUS IgG kit
(Mabtech) was used. The assay was performed as described in the man-
ufacturer’s protocol, and ASCs were added as indicated in the figures.
IGHV sequencing and analysis
For analysis of the Ig repertoire, IGHV regions were amplified from ran-
domly primed cDNA made from the flow-sorted CD19pos, CD19low, and
CD19neg PB fractions using tagged framework-1 BIOMED-2 primers and
proofreading Phusion polymerase to minimize amplification errors (28).
Following second-round indexing with Nextera NGS tags (Illumina), li-
braries were sequenced using MiSEquation 2 3 300-bp paired-end reads.
Resultant sequences were overlapped using FLASH (fast length adjust-
ment of short reads) (29) and uploaded to the Galaxy Web-based platform
(http://usegalaxy.org) for quality control and further analysis. These se-
quences were then groomed, trimmed, filtered to remove low-quality se-
quences (99% of sequence quality score . 20), and output as FASTA files
(30). The sequences were analyzed with HighV-QUEST (31); because of
the large number of sequences generated and limitations on IMGT sub-
missions, the FASTA files were split into individual files of ,500,000
reads, and the results were joined back together using custom Python
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scripts. Nonproductive rearrangements and unknown rearrangements were
removed from the analysis, and the initial cell number was used to de-
termine the sequencing depth required per cell (reporting at a ratio of 0.5
reads per cell).
For comparisons, the 100 most frequent IGHV rearrangements from each
cell fraction were considered. Overlaps between IGHV rearrangements
between populations were restricted to sequences encoding identical
CDR3 amino acid sequences, including identical CDR3 lengths, with
identical Vand J family sequences (32). This restrictive approach excluded
rare events of identical CDR3 sequences associated with nonidentical
underlying V and J family sequence, as well as polymerase errors. Fur-
thermore, any bias in this approach tends to underestimate clonal lineage
relationships between populations, by not considering relationships be-
tween CDR3 sequences that differ as a result of somatic hypermutation. To
assess the extent of population overlap, Morisita–Horn (MH) indices (33)
were calculated in Excel for the top 100 IGHV rearrangements, defined as
above. Violin plots of somatic hypermutation distribution were generated
with ggplot2 in R. The overlap of the most prevalent clones in each sample
was displayed using Circos plots (34).
In vitro differentiation
Twenty-four–well flat-bottom culture plates (Corning) and IMDM sup-
plemented with GlutaMAX and 10% heat-inactivated FBS (Invitrogen)
were used, unless otherwise specified.
Days 0–3
B cells were cultured at 2.53 105 per milliliter with IL-2 (20 U/ml), IL-21
(50 ng/ml), and F(ab9)2 goat anti-human IgM and IgG (10 mg/ml) on
gamma irradiated CD40L-expressing L cells (6.25 3 104 per well). R848
(1 mg/ml) was used instead of CD40L where specified.
Days 3–6
At day 3, cells were detached from the CD40L L cell layer and reseeded at
1 3 105 per milliliter in media supplemented with IL-2 (20 U/ml), IL-21
(50 ng/ml), HybridoMax hybridoma growth supplement (11 ml/ml), Lipid
Mixture 1, Chemically Defined, and MEM Amino Acids Solution (both at
13 final concentration).
Day 6 onward
For extended lifespan maintenance, day-6 cells were harvested and
recultured, at 3 3 105 cells per well (total volume 2.1 ml), in the upper
compartment of a 12-well Transwell insert (clear polyester membrane,
0.4-mm pore; Corning). Gamma irradiated M2-10B4 stromal cells were
seeded into the lower chamber, at 8.32 3 104 per well, proportionally.
Cells were grown in IMDM supplemented with IL-6 (10 ng/ml), IL-21
(50 ng/ml), IFN-a (100 U/ml), HybridoMax hybridoma growth supplement
(11 ml/ml), Lipid Mixture 1, Chemically Defined, and MEM Amino Acids
Solution. IL-21 was discontinued after day 13. Every 3.5 d, one half of the
media volume was exchanged. A detailed protocol is available on request.
Results
CD19neg PBs are present in the peripheral blood
LLPCs are enriched among CD19neg BM PCs and are thought to
derive from homing and residency of peripherally generated PBs/
PCs to the BM. It is not known whether CD19 loss is a gradual
process that is directly linked to PC age or whether it may be
established during the initial phase of ASC generation. To address
this question, we began by analyzing peripheral blood before and
after seasonal influenza vaccination in healthy donors. The pe-
ripheral blood contains populations of ASCs, which can be phe-
notypically defined and are thought to predominantly represent
recently generated PBs. However, more mature pre-existing PCs
displaced from niche environments in the context of immune re-
sponses may also be present among peripheral blood ASCs. Using
the gating strategy shown (Fig. 1A), we found a heterogeneous
pattern of CD19 expression among the SSClow, IRF4high, CD27high,
CD38high, CD20neg, CD95pos peripheral blood cells, including a
fraction that was CD19neg. To verify that the phenotypically de-
fined populations included functional ASCs we sorted CD20neg,
CD3neg, CD38high, CD27high cells into three fractions based on
CD19 expression levels (CD19pos, CD19low, and CD19neg) and
performed ELISPOT analysis focusing on IgG secretion (Fig. 1B).
This demonstrated that all three sorted populations included IgG-
secreting cells. The observed number of IgG spots as a proportion
of input cells appeared modestly reduced in the CD19neg fraction,
potentially consistent with a contribution from displaced BM PCs
with compromised function, but nonetheless demonstrating that
the CD3neg, CD19neg, CD20neg, CD27high, CD38high peripheral
blood fraction included functional ASCs.
Ag-specific CD19neg PBs are generated during acute immune
responses in humans
We next took advantage of seasonal influenza vaccination to ask
whether CD19neg PBs were generated as Ag-specific cells during
acute immune responses in human. To directly assess whether
CD19neg PBs included Ag-specific cells rather than simply dis-
placed BM PCs, we sorted the CD19pos, CD19low, and CD19neg
PB fractions from five donors at day 6 or 7 postinfluenza vacci-
nation and used these cells in ELISPOT assays against the vac-
cination Ag or against typhoid vaccine as an unrelated Ag. The
phenotypic PB fractions could be recovered from all donors, albeit
at differing frequencies. As expected, vaccine-specific IgG and
IgM responses were readily detectable from CD19pos PBs
(Fig. 2A, data not shown). Strikingly, in all donors, vaccine-
specific IgG Ab responses were also readily detectable from
CD19low and CD19neg PBs (Fig. 2A). Cell numbers precluded
parallel assessment of other isotype secretion from CD19neg PBs.
In the postvaccine response, there was no statistically significant
difference in the frequency of influenza vaccine-specific ASCs (as
determined by individual ELISPOTs) per input cell among any of
the three fractions (Fig. 2B). To further assess the specificity of the
detected PB response, donors were resampled after a 9-wk inter-
val, at which point the acute Ag-specific immune response would
be expected to have concluded. Indeed, after this interval, influ-
enza vaccine–specific Ab secretion was markedly reduced among
the peripheral blood PB fractions (Fig. 2C). Therefore, we con-
clude that Ag-specific CD19neg PBs are generated during the acute
influenza vaccine response in humans.
Kinetics of CD19low/neg PBs after influenza vaccination
We next analyzed the kinetic changes in peripheral blood PB
populations following vaccination. Because of the continuous
nature of the CD19 expression distribution and the scarcity of the
CD19neg fraction for these analyses, the CD19low and CD19neg PB
fractions were considered together (Supplemental Fig. 1A). The
overall PB response followed the expected course, with a sub-
stantial expansion in most donors within 6 d, followed by a sub-
sequent contraction with variable kinetics (Fig. 3A). Of note, one
donor showed a high baseline peripheral blood PB number, which
ultimately returned to lower levels on subsequent sampling. Al-
though there were no self-reported symptoms of infection or in-
flammatory process, we interpret the high baseline PBs in this
donor, with the eventual return to PB levels similar to other do-
nors, as representing evidence of an active immune response at
the time of initial sampling prior to immunization. CD19pos PBs
represented the major population at baseline, accounting for
.92% of PBs in all donors. Although CD19low/neg PBs did re-
spond numerically following immunization (Fig. 3B), this re-
sponse was of a lower magnitude than the corresponding increase
in CD19pos PBs, leading to a reduction in the percentage of
CD19low/neg PBs in the peripheral blood from a median of 5% at
baseline to 2% at day 6, with variable recovery toward steady-state
levels by day 20. In two donors, CD19neg PBs showed an extended
numerical response, with maintained absolute numbers at days 6
and 13 of sampling. This was mirrored in one of the two donors by
The Journal of Immunology 3
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a similarly extended response in total PB numbers at day 13.
Although the significance of this delayed kinetics is uncertain, a
similar variation in PB kinetics has been observed in tetanus
toxoid–specific immune responses (35). In all donors, the peak of
the absolute PB response occurred at day 6, consistent with pre-
vious reports. Furthermore, consistent with a direct involvement in
the Ag-specific immune response, the percentage of Ki67pos PBs
increased across CD19pos, CD19low, and CD19neg PBs (Fig. 3C,
Supplemental Fig. 1B). Thus, in the context of an acute in vivo
immune response to vaccination, CD19pos PBs represent the nu-
merically predominant responding population, although CD19low
and CD19neg PBs are present at the steady-state and during an
acute immune response in human peripheral blood.
CD19pos, CD19low, and CD19neg PBs express related IGHV
CDR3 sequences during the influenza vaccine immune responses
To further assess relationships among the peripheral blood PB
populations, we sorted CD19pos, CD19low, and CD19neg PBs from
four additional donors at day 6 after influenza vaccination and
performed repertoire sequencing of expressed IGHV rearrangements
from mRNA. Given the variation in population frequencies, a
different absolute number of input cells was recovered and se-
quenced for each population and donor. Across all samples, we
obtained $640,000 high-quality paired end-reads, leading to a
predicted read depth of$25 reads per cell (Supplemental Table I).
As expected, a wide range of unique IGHV sequences was re-
covered from the three phenotypic PB fractions across all donors.
This reflected, in part, the differences in overall population fre-
quency reflected in the cell number obtained from sorting. Indi-
vidual donors showed consistency across the pattern of IGHV
segment usage (Fig. 4A, Supplemental Fig. 2C) and the ratio of
unique IGHV sequences recovered per input cell across the three
PB fractions analyzed (0.33–0.35, 0.20–0.36, 0.63–0.74, and
0.42–0.70 for donors 1–4; Supplemental Table I). In each cell
fraction, and for each donor, some IGHV sequences were observed
at high frequency within a background of rare IGHV rearrange-
ments, particularly in the CD19pos fraction. In terms of IGHV gene
segment usage, the three PB fractions showed highly related
overall patterns in each donor (Fig. 4A, Supplemental Fig. 2C).
Consistent with derivation from an ongoing T-dependent immune
FIGURE 1. CD19neg PBs are a functional ASC population in the peripheral blood. (A) PBs were gated based on their scatter profile, intracellular
expression of IRF4, strong surface expression of CD27 and CD38, and negativity for CD24 and CD84. The expression of CD20 and CD19 within the
phenotypically defined PBs is shown in black against a background of other events in gray. Plots are representative of samples from three healthy vol-
unteers. (B) PBs (CD38high, CD27high, and CD20neg) were flow sorted into three fractions based on the expression level of CD19 (pos, low, neg) and
assessed by ELISPOT for the capacity to secrete IgG. The number of cells seeded in each well is indicated (a representative example of two independent
experiments is shown).
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response, the majority of IGHV sequences showed evidence of
somatic hypermutation, with a very similar average and distribu-
tion of somatic hypermutation load (Fig. 4B, Supplemental Fig.
2A, 2D). Using a cut-off of ,2% sequence divergence to iden-
tify unmutated IGHV sequences, there was no significant differ-
ence in the frequency of unmutated IGHV sequences in the three
populations (2.3–7.1, 2.3–4.8, and 2.0–5.2% of sequences in
the CD19pos, CD19low, and CD19neg fraction, respectively,
Supplemental Fig. 2B).
To address relationships among the phenotypic PB fractions, we
focused on the 100 most prevalent HCDR3 sequences obtained
from each of the three PB fractions. We considered overlaps among
the populations in a restrictive fashion as IGHV rearrangements
using identical IGHV and IGHJ gene segments and encoding
HCDR3s of identical amino acid sequences and length. By lim-
iting our assessment in this fashion, any bias favors an underes-
timate of relationships among the PB fractions. MH indices, which
provide a statistical measure of population dispersion (MH index = 0,
no overlap in terms of species/clones; MH index = 1, species/
clones occur in the same proportion in both samples), supported
a substantial degree of overlap among samples (Fig. 4C). Al-
though highest for the comparison between CD19low and CD19neg
fractions (MH indices 0.816–0.943), the degree of overlap also
remained substantial in the comparison between CD19pos and ei-
ther CD19low or CD19neg fractions for all four donors (MH indices
0.487–0.916 and 0.248–0.883, respectively). We used Circos plots
to visually display the overlap in IGHV rearrangements among
populations (Fig. 4D, Supplemental Fig. 2E). These plots illus-
trated the common contribution that shared IGHV rearrangements
encoding identical HCDR3 sequences made to the CD19pos,
CD19low, and CD19neg PB fractions in each donor. Most strikingly,
in one donor (donor 2), a single recurrent IGHV sequence accounted
for 1.4, 10, and 24% of sequence reads in the CD19pos, CD19low, and
CD19neg fractions, respectively (Fig. 4D); interestingly, this donor
FIGURE 2. CD19neg PBs generated following influenza vaccination include vaccine-specific ASCs. (A) ELISPOT results for two representative donors
are shown at peak of the postvaccine immune response (days 6/7) and after 63+ d. For each donor, PBs were sorted into CD19pos, CD19low, and CD19neg
fractions, as shown in Fig. 1B, and seeded at the densities shown (determined by PB recovery). ELISPOTs show detection with anti-IgG for plates coated
with immunizing influenza vaccine or with typhoid vaccine as negative control. During the peak immune response, the sorted CD3pos fraction was used as
an additional negative control. (B) A summary of influenza-specific ELISPOT results obtained from PB fractions of five independent donors is shown. Each
donor is shown as a different symbol, with lines connecting the respective results for each PB fraction as indicated on the x-axis. The y-axis shows the
fraction of influenza-specific ASCs detected as a proportion of input cells. Significance was calculated using a paired two-tailed t test. (C) ELISPOT results
are shown for donors as in (A), with samples taken at day 63+ after vaccination. Cell numbers used in each condition are indicated. A positive control was
provided by PBs derived at peak immune response and stored at 280˚C.
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had no previous history of influenza vaccination. Overall, this
analysis demonstrated that, during the acute response to influ-
enza vaccination in humans, CD19neg PBs are generated within
the first week following vaccination that share IGHV sequences
encoding identical HCDR3 sequences to those of PBs that retain
CD19 expression. Because the HCDR3 sequence is a primary
contributor to Ag specificity (36), and set alongside the data on
secretion of vaccine-specific Abs shown in Fig. 2, we conclude
that generation of Ag-specific CD19neg PBs is part of the in vivo
immune response to vaccination in humans.
CD19neg PCs are generated at the PB to PC transition in vitro
The in vivo analysis provides evidence for early generation of
CD19neg ASCs with the phenotypic characteristics of PBs during
Ag-specific immune responses. However, it is not possible to track
a precursor/product relationship with BM CD19neg PCs in these
analyses, and exploring in vivo ASC dynamics in humans repre-
sents a major challenge. To address the potential relationship
between early loss of CD19 and the generation of CD19neg PCs in
human cells, we turned to in vitro models of long-lived PC dif-
ferentiation. We (26) and other investigators (37) have described
models that allow the generation and maintenance of long-lived
human PCs in vitro. Both in the work of Jourdan et al. (37) and in
our model system for generation of human long-lived PCs, the
PCs generated in vitro were identified as CD19low. However we
noted in subsequent differentiations that this was not uniformly
the case and that subpopulations of CD19neg PCs were generated.
Differentiation of peripheral blood B cells to the PB state follows
a well-defined pattern leading to the generation of CD19pos PBs
from CD19pos activated B cells (Supplemental Fig. 3A). We pre-
viously showed that transfer of such PBs into conditions pro-
moting PC survival is accompanied by a cessation of cell
proliferation within 4 d of culture (day 10). This is further sup-
ported by our gene-expression analyses demonstrating extinction
of cell cycle and cell proliferation signatures over a similar
timeframe (26, 38). The change in proliferative capacity repre-
sents the primary functional criterion for the transition from PBs
to PCs (27) and correlates with the population level acquisition of
CD138 expression. Therefore, we examined the transition in the
CD19 expression state between the day 6 and day 10 time points
of the in vitro culture. Cells with very low/absent CD19 expres-
sion were established rapidly among maturing PBs; they were
evident as a very small proportion of CD138pos cells at day 6 of
culture, but they made up a substantially greater fraction of the
CD138pos population by day 10. Indeed, the levels of CD19 ex-
pression observed among in vitro–generated PCs (Supplemental
Fig. 3B) mirrored those observed among primary BM-derived PCs
(Supplemental Fig. 3C). As a percentage of PCs, the contribution
of CD19neg PCs varied from 1 to 44% across a range of donors at
day 10. On continued culture in most donors, the percentage of
CD19neg PCs increased, reaching a range of 9–47% (median 25%,
95% confidence interval 21–42%) by day 20 of in vitro culture (5)
(Fig. 5A). The increase in CD19neg PCs was statistically signifi-
cant at each successive time point of comparison, but it was most
significant during the initial transition from PB to PC (day 6
versus 10, p = 0.0009; day 10 versus 13, p = 0.0015; day 13 versus
20, p = 0.0179; paired t test). Thus, CD19neg PCs are generated
in vitro at early time points corresponding to the point of func-
tional and phenotypic transition to the PC state.
TLR-dependent B cell activation, mimicking a T-independent
response, generates CD19neg PCs in vitro
Models of PC differentiation can be broadly divided into those
using mimics of a T-dependent immune response utilizing CD40L
FIGURE 3. CD19neg PBs increase following influenza vaccination but
represent a minor fraction of peripheral blood PBs. The peripheral blood
numbers per milliliter of CD19pos PBs (A) and number of CD19neg PBs (B)
from six healthy volunteers who underwent seasonal influenza vaccination
are shown at the specified time points after vaccination (baseline imme-
diate prevaccination is t = 0). Individual donors are identified by the same
symbols and lines in each graph (gating strategies for cell enumeration are
shown in Supplemental Fig. 1A). (C) The percentage of Ki67pos PBs in the
CD19pos, CD19low, or CD19neg fractions from five individual donors are
shown (gating strategies for Ki67 detection are shown in Supplemental
Fig. 1B) at baseline and at peak PB response (day 6). Significance was
determined using a paired two-tailed t test.
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and those modeling T-independent immune responses via the TLR
pathway. Our existing model used CD40L as a principal signal to
drive PC differentiation. To assess whether emergence of CD19neg
PCs was differentially controlled depending on the mode of B cell
activation, we assessed the capacity of TLR ligation, as a mimic of
a T-independent immune response, to drive differentiation of
LLPCs in vitro. We found that a TLR7/8 agonist, in conjunction
with IL-21 and IL-2, efficiently generated populations of PBs with
a similar phenotypic transition to those generated by CD40L-
based differentiation (Supplemental Fig. 3D). On subsequent
transfer into the PC-maturation conditions, previously character-
ized as suitable for generation of LLPCs from CD40:CD40L-
derived PBs, maturation to CD138pos PCs and PC survival were
observed for PBs generated using TLR agonists (Supplemental
Fig. 3E). Thus, a differentiation system based on a synthetic
TLR7/8 agonist generated PBs that were competent for maturation
FIGURE 4. Clonal relationships of CD19pos, CD19low, and CD19neg PBs following influenza vaccination. Peripheral blood from four donors, following
seasonal influenza vaccination, was sorted into CD19pos, CD19low, and CD19neg PBs at peak immune response using the sorting strategy shown in Fig. 1B.
IGHV HCDR3 repertoire analysis was performed by next-generation sequencing, and analysis was performed using IMGT (see also Supplemental Fig. 2).
(A) Shown is the distribution of IGHV V-gene family usage across the three PB fractions in two independent donors. (B) The distribution of somatic
hypermutation load across the top 100 unique clones for the three PB fractions is shown from the same two donors (y-axis shows the percentage similarity
to germline sequence, where $98% is considered unmutated). (C) MH indices are shown for the degree of population overlap based on the top 100 unique
clones for the three PB fractions from each donor. (D) The clonal relationships for the top 100 clones are illustrated using Circos plots. Overlap of clones
between PB fractions was defined based on IGHV rearrangements encoding identical HCDR3 sequences of the same lengths using the identical V- and
J-gene segments. Values used in generating the plots were the percentage of sequence reads for each clone across all reads for the indicated cell type. The
three PB fractions are separated and indicated in the upper right of each plot. The clonal relationships are linked by joining ribbons, with the clonal
association indicated by color code, and at the common points of origin around the circumference of the plot. The widths of the ribbons reflect the
percentage of sequence reads for the indicated clone within each PB fraction.
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into LLPCs in vitro. Furthermore, PCs generated in response to a
TLR7/8 agonist showed a similar pattern of heterogeneous CD19
expression from early time points (Fig. 5B), and the percentage of
CD19neg PCs present increased with time of culture (Fig. 5C).
Thus, CD19neg PCs can be generated by stimuli mimicking
T-dependent (CD40) or T-independent (TLR) immune responses.
CD19neg PCs increase over time in vitro
Because absence of CD19 expression may be linked to PC lon-
gevity in vivo, we examined CD19 expression in PCs over extended
in vitro cultures. Experiments performed using total unfractionated
PBs or PBs sorted at day 6 into CD27high and CD27low populations
demonstrated a consistent increase in the fraction of CD19neg PCs
over time (Fig. 6A). A rapid increase in the percentage of CD19neg
PCs generated by days 20–30 was followed by a gradual increase
to day 100 in both experimental contexts as total PC number
declined toward a plateau phase (Fig. 6B, 6C). Thus, CD19neg PCs
increase as a percentage of in vitro–generated LLPCs with ex-
tended culture.
CD19neg and CD19pos PCs can be maintained independently
The early establishment of CD19neg PCs in vitro paralleled the
early generation of CD19neg ASCs in vivo. However, the contin-
ued presence of CD19neg PCs over time in vitro could be con-
sistent with preferential survival of CD19neg PCs, or it could
represent a subsequent age-associated transition in PC phenotypes
with gradual loss of CD19 expression. To address these possibil-
ities, we separated CD19neg and CD19pos PC fractions at day 10 or
16 of in vitro culture, achieving .99.6% purity of CD19neg PCs,
and seeded these along with the CD19pos PC–enriched populations
into extended in vitro cultures (Fig. 7A). For sorted CD19neg and
CD19pos fractions, cell numbers initially declined postsort but then
FIGURE 5. CD19neg PCs are generated during the PB to PC
transition in vitro. (A) The proportion of CD19neg PCs among
total PCs is illustrated in the line graph at the specified time
points during in vitro differentiation. The day-6 point (when
PBs were transferred into PC conditions) is indicated by an
arrow on the x-axis. PCs were defined as Annexin-V, 7-AAD,
CD20 negative, and CD38, CD138 positive. Two-tailed paired
t test values are shown for comparison between time points.
(B) Graphs show levels of CD19 expression by PCs generated
in vitro with CD40L (left panels) or TLR stimulation (right
panels) compared with isotype controls (dashed line) on days
10 and 42. (C) Proportion of CD19neg PCs among total PCs
generated in vitro using CD40L (solid lines) or TLR (dashed
lines) stimulation at the specified time points in donor 1 (d),
donor 2 (▴), and donor 3 (♦). Data are representative of three
donors used in two different experiments.
FIGURE 6. The proportion of CD19neg PCs increases with
time during extended in vitro culture. (A) Graphs showing
changes in CD19 expression among in vitro–generated PCs
(defined as CD20neg CD38pos CD138pos) during culture to day
107. Data shown are representative of three replicates over
two experiments. (B) CD19neg PCs generated in vitro from
day-6 unsorted PBs or sorted on day 6 based on CD27 ex-
pression are shown as a proportion of total PCs during ex-
tended cultures. Data derive from independent experiments
with unsorted (n) or sorted PBs (CD27high [▴]; CD27low [d]).
(C) Normalized numbers of CD19pos and CD19neg PCs de-
tected per well shown at the specified time points of extended
in vitro culture data derive from the same differentiations as in
(B). CD19pos PCs (solid lines) and CD19neg PCs (dashed lines)
derived from unsorted PBs (n), sorted CD27high PBs (▴), and
sorted CD27low PBs (d). PCs were defined as Annexin-V,
7-AAD, and CD20 negative, CD38 and CD138 positive.
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tended toward a plateau phase, as previously observed for total
PCs in such cultures (Fig. 7B). Furthermore, within the enriched
CD19pos fraction, the percentage of CD19pos cells remained stable
over time, showing a ,5% change at any time point. We conclude
that CD19neg PCs generated early during differentiation can be
maintained independently of the bulk CD19pos population in vitro
for at least several weeks.
Discussion
There is now increasing evidence in humans that LLPCs are
enriched among the CD19neg PC population within the BM and the
small intestine (5, 16, 17). Therefore, the origins of such cells are
of substantial interest. In this study, by examining the phenotype,
function, Ag specificity, and IGHV-rearrangement repertoire of
peripheral blood ASCs generated following seasonal influenza
vaccination in healthy subjects, we provide evidence for the early
emergence of Ag-specific CD19neg ASCs during a human in vivo
immune response.
It is not possible to track the relationship of these cells to the
subsequent establishment of long-lived vaccine-specific PCs in the
BM or elsewhere. These populations might plausibly still derive
from CD19pos PBs, which represent the bulk of PBs generated
during the immune response, with age-associated loss of CD19
after seeding of an appropriate niche. However, our data provide an
important proof of principle that CD19 loss can be established in a
subset of PBs at an early stage of the immune response and, thus,
at an early stage of the overall ASC life cycle. Interestingly, in
recent data using carbon-14–based assessments of average PC age
from human small intestine, of six donors tested, two were found
to have CD19neg PCs in the CD45pos fraction with an average age
indistinguishable from CD19pos PCs and estimated as ,1 y (5).
Although in vitro model systems cannot fully recapitulate the
in vivo situation, they do provide the opportunity to address
precursor/product relationships at a cellular level. In the context of
such an in vitro model, our data indicate that CD19neg PCs gen-
erated early during differentiation can persist in this state and can
be maintained independently of the bulk CD19pos PC population
for at least several weeks. We are not able to track the fate of
CD19neg PBs generated early during differentiation in vivo. Thus,
we cannot assess whether these directly or preferentially con-
tribute to the LLPC population in BM or small intestine, nor can
we conclude that CD19pos PBs generated as the dominant element
of the in vivo immune response do not contribute to establishment
of the CD19neg LLPC population through gradual loss of CD19 as
the PCs age in an appropriate niche in vivo. However, we do
consider that our data provide the basis for suggesting an alternate
model: CD19neg PBs/PCs generated early during an Ag-specific
immune response may be recruited into supportive niche envi-
ronments having lost CD19 expression before or just as they enter
into the niche. If the CD19neg PB/PC fraction generated early
during an immune response were preferentially enriched for cells
capable of seeding the LLPC compartment, this would have im-
portant implications for understanding the generation and main-
tenance of long-lived humoral immunity. However, we emphasize
that, although we consider that our data open this possibility for
future study, the results do not provide direct evidence to dispute
the potential origin of CD19neg LLPCs as a result of gradual age-
associated loss of CD19 expression.
Our ability to detect influenza vaccine–specific CD19neg PBs
early during seasonal influenza vaccination responses contrasts
with the results of Mei et al. (16), who reported a failure to detect
Ag-specific CD19neg PBs in the peripheral blood over a time
course following tetanus toxoid vaccination. In their work, Mei
et al. used intracellular flow cytometry for tetanus toxoid binding
and cytoplasmic IgG staining to identify vaccine-specific ASCs.
Intracellular staining provides a surrogate for secretory function
and depends on detection of retained intracellular Ig following
permeabilization, whereas ELISPOT provides a standard for de-
tection of functional ASC populations. Therefore, it is possible
that the explanation for the difference in results lies, in part, in the
assays used, as well as the absolute number of events and volume
of peripheral blood sampled to identify the rare CD19neg PB
fraction. Equally, the nature of the vaccinating Ag and the number
of preceding vaccinations may impact on the frequency of CD19neg
PBs generated. In the case of influenza vaccination, the quality of
the pre-existing immune response and donor vaccination history
impact on the nature and magnitude of the detectable PB response,
in particular when the same Ag is re-encountered (39–41).
In the steady-state, the peripheral blood PB population is thought
to derive primarily from mucosal immune responses (42) and is
enriched for IgA class-switched cells. In contrast, following a
variety of vaccination approaches or during acute viral infection,
dominant PB responses are generated, with kinetics generally
peaking around days 6–7 postvaccination (35, 43, reviewed in Ref.
44). Such peripheral blood PBs are enriched for IgG-secreting
cells and bear IGHV sequences with somatic hypermutations
FIGURE 7. In vitro–generated CD19neg PCs can be main-
tained independently of bulk CD19pos PC fraction. PCs gen-
erated in vitro from peripheral blood B cells of healthy
volunteers were sorted based on their CD19 expression on day
10 or 16 and maintained in vitro with conditions supporting
PC survival. (A) Graphs showing changing levels of CD19
expression at the indicated days by PCs sorted on day 16
based on surface CD19. (B) The total numbers of CD19pos
(upper panel) and CD19neg (lower panel) PCs maintained at
the specified time points following flow sorting are shown. d,
donor 1 (day 10 sort); ▴, donor 2 (day 16 sort); ♦, donor 3
(day 16 sort).
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consistent with derivation from germinal center–experienced
B cells (35, 45). The rapidity of their generation and high somatic
hypermutation loads have been taken as evidence that such PBs
derive from pre-existing memory B cells but not excluding the
potential contribution of germinal center re-entry prior to re-
emergence in the peripheral blood as a PB population with ad-
ditional mutational diversity (35). Origin from a diverse memory
B cell pool was also supported by longitudinal tracking of influ-
enza vaccine–specific PBs over sequential years (41). The data
presented in this article demonstrate that populations of CD19neg
PBs are present in the peripheral blood of healthy individuals
in the absence of active infection or inflammation, as well as
contributing to the expanded and proliferating Ag-specific im-
mune response following vaccination. Thus, a capacity to generate
functional Ag-specific CD19neg ASCs is evident in vaccine re-
sponses of adult donors, and this capacity can be manifest in
in vitro differentiations mimicking T-dependent or T-independent
responses to the PC stage. Given the IGHV repertoire similarities
that we observe, it is likely that, as for the dominant CD19pos PB
response, the CD19neg PB population derives from pre-existing
memory B cells in Ag-experienced donors.
The basis on which variable loss of CD19 is established during
commitment to the PC state remains to be determined and might
be influenced by the heritage of the differentiating B cell and the
nature of the differentiation stimulus. The high degree of overlap
between the in vivo PB fractions identified at the level of IGHV
sequence strongly supports origin from a common precursor
during the process of differentiation. The emergence of CD19neg
PB/PCs could represent more rapid progressive differentiation in
one daughter cell relative to another, or it could be established in
a deterministic or stochastic fashion among the differentiating
population. There is considerable debate regarding the relative
importance of deterministic and stochastic influences on decisions
operating during the immune response (46–49). During PC dif-
ferentiation, a central model links the process of cell division to
stochastic choices of alternate fates, including class switching,
differentiation, further division, or cell death in dividing activated
B cell/PBs (46). It has been proposed that the timing of such
potentially competing fates is determined at the initial point of cell
activation/birth and may be influenced by subsequent exposure to
stimuli within a family tree of differentiating lymphocytes (48).
Thus, it is conceivable that the heterogeneity in CD19 expression
among PBs sharing identical IGHV rearrangements, and thus
presumed to belong to the same family tree, is established in a
fashion related to this and might be explained mechanistically at
the level of differential gene regulation. In this context, the heri-
tage of the differentiating B cell and the nature of the instructive
signal might be linked to the likelihood of related daughter cells
establishing CD19 repression. Alternatively, in a progressive dif-
ferentiation model, the cells most rapidly and completely losing
CD19 expression would be more advanced in terms of differen-
tiation. Although not excluding this explanation, our failure to
observe CD19pos PCs progressing to a CD19neg state at a signif-
icant rate during in vitro culture after sorting argues against the
view that, in the short-term, CD19pos PB/PCs are lagging behind
the CD19neg PB/PCs in terms of the extent of differentiation.
Therefore, in future work, it will be important to evaluate in more
detail the factors influencing the establishment of the CD19neg
PCs generated early during differentiation. The data presented in
this article provide proof-of-principle for the generation of vaccine
Ag–specific CD19neg ASCs early during human immune re-
sponses, indicating that heterogeneity in the extent of CD19 re-
pression can be established during the initial transition of PBs to
PCs and is not strictly dependent on PC ageing.
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